CoChat

Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer

Open access
Durinikova, Erika, Reilly, Nicole M., Buzo, Kristi, Mariella, Elisa, Chilà, Rosaria, Lorenzato, Annalisa, Dias, João M. L., Grasso, Gaia, Pisati, Federica, Lamba, Simona, Corti, Giorgio, Degasperi, Andrea, Cancelliere, Carlotta, Mauri, Gianluca, Andrei, Pietro, Linnebacher, Michael, Marsoni, Silvia, Siena, Salvatore, Sartore-Bianchi, Andrea, Nik-Zainal, Serena, Di Nicolantonio, Federica, Bardelli, Alberto, Arena, Sabrina · 2022 · Clinical Cancer Research
Cited by 59

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Purpose: Genomic instability is a hallmark of cancer and targeting DNA damage response (DDR) is emerging as a promising therapeutic strategy in different solid tumors. The effectiveness of targeting DDR in colorectal cancer has not been extensively explored. Experimental Design: We challenged 112 cell models recapitulating the genomic landscape of metastatic colorectal cancer with ATM, ATR, CHK1, WEE1, and DNA-PK inhibitors, in parallel with chemotherapeutic agents. We focused then on ATR inhibitors (ATRi) and, to identify putative biomarkers of response and resistance, we analyzed at multiple levels colorectal cancer models highly sensitive or resistant to these drugs. Results: We found that around 30% of colorectal cancers, including those carrying KRAS and BRAF mutations and unresponsive to targeted agents, are sensitive to at least one DDR inhibitor. By investigating potential biomarkers of response to ATRi, we found that ATRi-sensitive cells displayed reduced phospho-RPA32 foci at basal level, while ATRi-resistant cells showed increased RAD51 foci formation in response to replication stress. Lack of ATM and RAD51C expression was associated with ATRi sensitivity. Analysis of mutational signatures and HRDetect score identified a subgroup of ATRi-sensitive models. Organoids derived from patients with metastatic colorectal cancer recapitulated findings obtained in cell lines. Conclusions: In conclusion, a subset of colorectal cancers refractory to current therapies could benefit from inhibitors of DDR pathways and replication stress. A composite biomarker involving phospho-RPA32 and RAD51 foci, lack of ATM and RAD51C expression, as well as analysis of mutational signatures could be used to identify colorectal cancers likely to respond to ATRi.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-22-0875

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 59

Metadata

Authors
Durinikova, E., Reilly, N. M., Buzo, K., Mariella, E., Chilà, R., Lorenzato, A., Dias, J. M. L., Grasso, G., Pisati, F., Lamba, S., Corti, G., Degasperi, A., Cancelliere, C., Mauri, G., Andrei, P., Linnebacher, M., Marsoni, S., Siena, S., Sartore-Bianchi, A., Nik-Zainal, S., Di Nicolantonio, F., Bardelli, A., & Arena, S.
Venue
Clinical Cancer Research
Published
2022-07-26
Volume
28
Issue
17
Pages
3874-3889
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W4288042084
Cited by
59
References
18
FWCI
3.38
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-22-0875
The paper
Durinikova, E., Reilly, N. M., Buzo, K., Mariella, E., Chilà, R., Lorenzato, A., Dias, J. M. L., Grasso, G., Pisati, F., Lamba, S., Corti, G., Degasperi, A., Cancelliere, C., Mauri, G., Andrei, P., Linnebacher, M., Marsoni, S., Siena, S., Sartore-Bianchi, A., . . . Arena, S. (2022). Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-22-0875

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.